New Triple-Drug cocktail aims to beat back tough leukemia
NCT ID NCT03661307
First seen Jun 24, 2026 · Last updated Jul 22, 2026 · Updated 5 times
Summary
This study is testing a combination of three drugs—quizartinib, decitabine, and venetoclax—in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The goal is to find the safest dose and see if the combination improves remission rates. The trial is for patients who are older or whose cancer has returned.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- quizartinib, decitabine, and venetoclax
- What this could lead to
- If this works, it could offer a new treatment option for people with acute myeloid leukemia who cannot tolerate intensive chemotherapy.
- What could go wrong
- This is an early-phase trial with only 73 participants, so results may not apply to everyone. The drug combination may cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?